Literature DB >> 32435888

Chiari I malformation with neurogenic hypertension after suboccipital decompression.

Abdulelah A Alluhaybi1,2, Sarah Bin Abdulqader3, Turki Alanazi3, Khalid Altuhayni3, Ayman Albanyan3.   

Abstract

Patients with Chiari I malformations have a spectrum of symptoms related to craniocervical structural compression. Neurogenic hypertension has been reported in some patients with this disorder, with resolution of hypertension after suboccipital decompressions in some cases. The pathophysiology of neurogenic hypertension in these patients is thought to be related to ventrolateral medullary compression. The important role of the ventrolateral medulla in blood pressure control has been studied extensively. In this report, we present the case of a pediatric patient diagnosed with a Chiari I malformation who developed hypertension after a suboccipital decompression. We believe that this case demonstrates the important role of the ventrolateral medulla in neurogenic hypertension.

Entities:  

Keywords:  Chiari malformation; Neurogenic hypertension; Suboccipital decompression; Ventrolateral medulla

Mesh:

Year:  2020        PMID: 32435888     DOI: 10.1007/s00381-020-04670-y

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  3 in total

1.  Clinical observations on etiology of essential hypertension.

Authors:  P J Jannetta; H M Gendell
Journal:  Surg Forum       Date:  1979

2.  Cessation of chronic hypertension after posterior fossa decompression in a child with Chiari I malformation. Case report.

Authors:  R Shane Tubbs; John C Wellons; Jeffrey P Blount; W Jerry Oakes; Paul A Grabb
Journal:  J Neurosurg       Date:  2004-02       Impact factor: 5.115

3.  Is Chiari malformation a cause of systemic hypertension and sinus bradycardia? A case report and literature review.

Authors:  Majid Ghasemi; Khodayar Golabchi; Vahid Shaygannejad; Majid Rezvani
Journal:  J Res Med Sci       Date:  2011-01       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.